<DOC>
	<DOCNO>NCT02058992</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy ramelteon ( Rozerem ) use routine clinical setting patient sleep-onset difficulty associate insomnia .</brief_summary>
	<brief_title>Ramelteon Tablets 8mg Drug Use Surveillance : Survey Insomnia Associated With Sleep-onset Difficulty</brief_title>
	<detailed_description>This drug use surveillance plan examine safety efficacy ramelteon tablet use routine clinical setting patient sleep-onset difficulty associate insomnia ( plan sample size , 3000 ) The usual adult dosage 8 mg ramelteon administer orally daily bedtime .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<criteria>1 . Sleeponset difficulty associate insomnia 1 . Patients previous history hypersensitivity ingredient Rozerem Tablets 2 . Patients severe liver dysfunction 3 . Patients take fluvoxamine maleate</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>